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Abstract Hepatocellular carcinoma (HCC) is a highly che-
moresistant cancer with no effective systemic therapy. De-
spite of surgical or locoregional therapies, prognosis
remains poor because of high tumor recurrence or progres-
sion, and currently, there are no well-established effective
adjuvant therapies. Glypican-3 (GPC-3) is specifically over-
expressed in hepatoma and perhaps is a valuable molecular
target for HCC therapy. In this present study, the effect of
silencing GPC-3 gene transcription on human HepG2 cell
proliferation was investigated by constructing GPC-3 short
hairpin RNA (shRNA) plasmid. After HepG2 cells were
transfected with the most efficient shRNA, GPC-3 mRNA
expression (90.4 %) was inhibited significantly and estimat-
ed by fluorescence quantitative reverse transcriptase-
polymerase chain reaction, and the result was accordance
with downregulation at the protein level. The percentage of
the cell proliferation was down to 28.9 % in the shRNA
group and 19.9 % in the shRNA plus sorafenib group. The
cell cycles were arrested in the G1 phase (65.6 %) and the
apoptosis rate was increasing (66.75 %) in the shRNA1
group with significant alteration compared with that in the
negative-shRNA group. Specific shRNA might intervene
effectively GPC-3 activation and inhibit tumor cell prolifer-
ation, suggesting that GPC-3 gene should be a potential
molecular target for HCC therapy.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide and its incidence is still in-
creasing [1, 2]. While the primary curative treatment for
HCC is surgical resection, a major obstacle for its treatment
is the high frequency of tumor recurrence even after curative
resection [3, 4]. Approximately 85 % of HCCs are not
candidates for curative treatments at the time of diagnosis;
hence, palliative modalities (transcatheter arterial chemo-
embolization, radiofrequency ablation, systemic chemother-
apy) are used [5, 6]. An increasing knowledge in molecular
biology of HCC will increase the possibilities of targeted
Dandan Yu and Zhizhen Dong contributed equally to this work.
D. Yu :W. Wu : L. Qiu :W. Sai :D. Yao (*)
Research Center of Clinical Medicine, Affiliated Hospital of
Nantong University, 20 West Temple Road,
Nantong 226001, Jiangsu Province, China
e-mail: yaodf@ahnmc.com
Z. Dong
Department of Diagnostics, Medical School of Nantong
University, 19 Qixiu Road,
Nantong 226001, Jiangsu Province, China
M. Yao :M. Yan
Medical School, Nantong University, 19 Qixiu Road,
Nantong 226001, Jiangsu Province, China
X. Yan : J. Chen
Institute of Clinical Oncology, Affiliated Hospital of Nantong
University, 20 West Temple Road,
Nantong 226001, Jiangsu Province, China
Tumor Biol. (2013) 34:661–668
DOI 10.1007/s13277-012-0593-y
therapy [7, 8]. Molecularly targeted therapies have recently
expanded the options available for advanced HCC [4, 9, 10].
The inhibitions of mTOR (rapamycin), VEGF (sunitinib),
EGF (erlotinib), and multi-tyrosine kinases (sorafenib) are
promising [11]. Alteration of the Wnt pathway, retinoid
compounds, inhibition of cell cycle as well as the proteo-
some, and epigenetic therapy can be other potential prom-
ising targets for HCC [12].
Glypican (GPC) is a family of heparan sulfate pro-
teoglycans that are bound to the cell surface by a lipid
anchor [13]. Members (GPC-1–6) of this family have
been identified in mammals. Glypican-3 (GPC-3) is
located at Xq26.1 area on chromosome and promotes
hepatoma cell growth by stimulating canonical Wnt
signaling. There is increasing evidence indicating that
the structural requirements for GPC-3 activation are
cell-type specific, and its core protein is processed by
a furin-like convertase [14, 15]. Recent studies have
revealed that GPC-3 is specifically overexpressed in
HCC tissues, and oncofetal antigen glypican-3 has been
a promising early diagnostic marker for HCC diagnosis
and prognosis [16–18]. However, the effect of the
downregulation of GPC-3 expression on hepatoma cell
proliferation was still not clearly defined. In this present
study, a specific short hairpin RNA (shRNA) was
screened and applied to silence GPC-3 gene transcrip-




Human HepG2 cell lines, obtained from the Chinese Acad-
emy of Sciences (Shanghai, China), show a high expression
of GPC-3, which is in contrast to its parental tumor. Cells
were cultured in high glucose Dulbecco’s modified Eagle’s
medium (DMEM; Gibco BRL, USA) supplemented with
10 % heat-inactivated fetal bovine serum (Gibco BRL,
USA) in a 5 % CO2-humidified atmosphere at 37 °C.
Plasmid constructs and transfection
Four pairs of GPC-3-shRNA targeting different sites of GPC-
3 gene were designed according to human GPC-3 sequence
(GenBank: BC035972), synthesized, and then constructed
(GenePharma Co., Ltd., Shanghai, China; Table 1). After
annealing and primer extension, shRNAs were inserted into
pGPU6/GFP/Neo vector and transformed into Escherichia
coli for screening. The pGPU6/GFP/Neo-negative control
vector contains a shRNA sequence that does not suppress
the expression of human GPC-3 gene. All the inserted sequen-
ces were confirmed by BamH I and Pst I digestion and
sequencing. The transfection reagent GenJetTM DNA In Vitro
Transfection Reagent for HepG2 Cells (Ver. II; SignaGen,
Gaithersburg, MD, USA) was used to transfect shRNA plas-
mid vector into HepG2 cells according to the manufacturer’s
protocol. In brief, HepG2 cells were plated in six wells at 18 to
24 h prior to transfection so that the monolayer cell density
reached to 60–70 % confluency for use.
Complete culture medium with serum and antibiotics is
freshly added to each well 60 min before transfection. Dilute
2 μg of DNA and 6 μL of GenJet™ reagent were added into
200 μL of serum-free DMEM with high glucose. Then, this
mixture was vortexed gently and spin down briefly to bring
drops onto each well. The mixture was homogenized by
gently swirling the plate and was incubated at 37 °C. At
12 h posttransfection, the DNA/GenJet™ complex-
containing medium was removed and replaced with a com-
pletely fresh serum-containing medium, and a second iden-
tical transfection was then carried out 24 h later. After the
first transfection at 48 h, GPC-3mRNA or protein levels in the
harvested cells were analyzed by fluorescence quantitative
reverse transcriptase-polymerase chain reaction (FQ-RT-
PCR) and Western blotting, respectively. The transfection
Table 1 Oligonucleotide sequences of GPC-3 shRNA in pGPU6/GFP/Neo vector
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cells were diluted (1:10) and stably transfected in a medium
containing G418 (400 μg/mL) for 2 weeks and maintained
with 200μg/mL for 3 weeks; the individual clone was isolated
and expanded.
RNA extraction
Total RNA was extracted using TRIzol reagent (Invitrogen,
USA) by following the manufacturer’s instructions. Briefly,
after HepG2 cells were transfected with or without shRNA
at 48 h, the cells (1×106) were harvested and washed twice
with cold phosphate-buffered saline (PBS). For each well,
1.0 mL TRIzol reagent was added; then, RNA was precipi-
tated by isopropanol, washed with 75 % ethanol, dissolved
with 20 μL DEPC (0.1 %), and quantified using a UV
spectrophotometer.
FQ-RT-PCR
Reverse transcription was carried out by using the Rever-
tAidTM First Strand cDNA Synthesis Kit (MBI Fermentas,
Vilnius, Lithuania) according to the standard protocol. In
brief, in a 20-μL reaction mixture containing 2 μg RNA and
oligo primers, at 42 °C for 1 h, cDNA was synthesized by
PCR using SYBR®Premix Ex TaqTMII (TaKaRa, Dalian,
China) with primers. The primers were GPC-3 forward: 5′-
CGAGATAAGCACCTTTCACAACC-3′, GPC-3 reverse:
5′-AGAAGAAGCACACCACCGAGA-3′ (NM_004484),
and GAPDH forward: 5′-CAAGGTCATCCATGACA
ACTTTG-3′and reverse: 5′-GTCCACCACCCTGTT
GCTGTAG-3′ (NM_017008). PCR was performed as fol-
lows: 30 s of predegeneration at 95 °C, 5 s at 95 °C, and 45 s
at 60 °C for 40 cycles with Rotor Gene 3000 thermal cycling
instrument (QIAGEN, Valencia, CA). GPC-3 gene and
GAPDH gene were amplified in the same reaction as an
internal loading control. The amplification specificity was
confirmed by the melting curves, the fluorescence was col-
lected at 60 °C (n05), and the relative quantitative results
were analyzed by the 2−ΔCt values.
Protein extraction
The transfected cells were harvested and washed with cold
PBS twice and then lysed on ice in RIPA buffer (1× PBS, 1 %
NP-40, 0.1 % sodium dodecylsulfate (SDS), 5 mM EDTA,
0.5 % sodium deoxycholate, and 1 mM sodium orthovana-
date) that contained 100 μg/mL phenylmethylsulfonyl fluo-
ride and protease inhibitors (KeyGen, Nanjing, China).
Western blotting
Approximately 50 μg of protein from each sample was
separated using a 10 % SDS–polyacrylamide gel, and it
was electrotransferred to polyvinylidene fluoride mem-
branes and blocked in 5 % nonfat dry milk in Tris-
buffered saline, pH 7.5 (100 mM NaCl, 50 mM Tris, and
0.1 % Tween-20). The transferred membranes were incubat-
ed with anti-GPC-3 (Abcam, USA) and anti-β-actin primary
antibodies (Beyotime, China) overnight at 4 °C, followed by
incubation with horseradish peroxidase-conjugated rabbit/
mouse anti-goat secondary antibodies. Proteins were
detected by Quantity One software (Bio-Rad, Laboratories,
Inc., USA) using Immobilon ECL Chemiluminescence HRP
Substrate (Millipore, Merck, USA).
Cell proliferation
After transfection for 48 h, cells were seeded in 96-well
plates with optical density to adapt to the different time
points. Cell proliferation was analyzed by an 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay according to the manufacturer’s instruction (Beyo-
time, China). In brief, after cells were seeded for 4 h,
10 μL of MTT was added into the medium (final, 0.5 mg/
mL) and the wells were incubated for 4 h at 37 °C to allow
formation of dark blue formazan crystal. The medium was
carefully removed with a pipette and 100 μL of dimethyl
sulfoxide was added. The mixture was shaken gently and
was equilibrated to room temperature to detect absorbance
(n05) at 570 nm with Synergy HT Multi-Detection Micro-
plate Reader (Bio-Tek, USA).
Cell cycles
HepG2 cells were infected with pGPU6/GFP/Neo-GPC-3
shRNAvector for 72 h. The cells with or without transfected
vector were harvested, trypsinized, washed with PBS, and
fixed in 70 % precooled ethanol for 24 h at 4 °C. Fixed cells
were stained with propidium iodide with RNase A cocktail
at 37 ° for 30 min. Data were obtained using FACSCalibur
flow cytometer (BD Biosciences, USA).
Cell apoptosis
The effective apoptosis of transfected cells were evaluated
by the PE-labeled Annexin-V/7-AAD assay and DNA-
ladder electrophoresis according to the manufacturer’s pro-
tocol. In brief, HepG2 cells (2×105) were collected, rinsed
twice in cold PBS, and added with binding buffer; then,
apoptosis rate was analyzed. By DNA-ladder electrophore-
sis, the apoptosis level was verified as follows: the cells (1×
106) were trypsinized, added with RNase A and protease K,
lysed at 70 °C for 10 min, extracted DNA from the mixture
by purification pillar, electrophoresized on 2 % agarose gel,
and then analyzed by an ultraviolet transilluminator with
Quantity One software (Bio-Rad, Laboratories, Inc., USA).
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Statistical analysis
Data were presented as mean ± standard deviation (SD) and
subjected to one-way analysis of variance. Differences be-
tween groups were examined by Student’s t test unless
otherwise noted. Statistical significance was accepted at
the level of P value less than 0.05 by using SPSS 17.0
software.
Results
Efficiency of GPC-3-shRNA plasmid screening
The different kinds of GPC-3shRNAs were synthesized
according to the GPC-3 sequence including the negative
shRNA (Table 1), were inserted into pGPU6/GFP/Neo vec-
tors, and constructed containing shRNA plasmids. All the
inserted sequences, confirmed by sequencing or by endonu-
clease BamH I and Pst I enzymatic digestion, and efficiency
of shRNA transfection are shown in Fig. 1. The inserted
fragments in plasmids verified the constructed plasmids
correctly and successfully for transfection with a
transfection reagent (Fig. 1a–d). HepG2 cells were trans-
fected with the following plasmids: pGPU6/GFP/NeoGPC-
3shRNA1 (shRNA1), pGPU6/GFP/NeoGPC-3 shRNA2
(shRNA2), pGPU6/GFP/NeoGPC-3shRNA3 (shRNA3),
and pGPU6/GFP/ NeoGPC-3shRNA4 (shRNA4). The cells
with a higher efficiency (over 80 %) at 24 h were observed
under selected visual fields (n05/each) at random with an
inverted fluorescence microscope for counting transfected
cells (Fig. 1b, 1f).
Downregulation of GPC-3 expression by shRNA
transfection
After HepG2 cells were transfected with different
shRNAs at 24 h, the suppression of GPC-3 expressions
at gene transcriptional level analyzed by FQ-RT-PCR is
shown in Table 2. Different silencing efficiencies were
observed after the cells were transfected with shRNAs,
and the inhibited rate of GPC-3 mRNA was 90.4 % in
shRNA1, 77.6 % in shRNA2, 46.8 % in shRNA3, and
15.3 % in shRNA4. No significant difference exists
between the negative-shRNA (neg-shRNA) group and
the control group. shRNA1 was one of the best plas-
mids with high efficiency (t021.786, P<0.001). The
same interference effects were observed in shRNA1
(P<0.001), shRNA2 (P<0.01), and shRAN3 (P<0.05),
and no statistical difference in the shRNA4 was ob-
served. The different inhibition efficiencies at protein
level were evaluated by Western blotting (Fig. 2a).
shRNA1 was one of the best specific plasmids for
GPC-3 (Fig. 2b), indicating that the highly specific
and efficient shRNA1 could suppress the GPC-3 activa-
tion in hepatoma cells at the gene transcriptional or
protein level.
Fig. 1 Construction, enzymatic digestion of plasmids, and shRNA
transfection efficiency. GPC-3-shRNAs were inserted into pGPU6/
GFP/Neo vector and constructed containing shRNA plasmids. The
shRNA plasmids were confirmed by enzyme digestion. a, c Pst I and
b, d, BamH I. HepG2 cells were transfected according to the preopti-
mized instructions as described in “Materials and methods.” At 24 h,
after the HepG2 cells were transfected with different shRNAs, the cells
were then harvested and checked. The phase-contrast (e) and fluores-
cence (f) photomicrographs (×100 magnification) of the cells trans-
fected with different constructed shRNA plasmids with or without
green fluorescent protein at 24 h
Table 2 Relative quantitative analysis of GPC-3 mRNA expression








Control 1.05±0.05 0 – –
Negative-shRNA 1.02±0.04b 2.86 0.781 0.984
GPC-3-shRNA1 0.11±0.06b 90.4 21.786 <0.001
GPC-3-shRNA2 0.23±0.12b 77.6 28.921 <0.001
GPC-3-shRNA3 0.57±0.13b 46.8 5.873 <0.001
GPC-3-shRNA4 0.89±0.06b 15.3 3.691 0.054
mRNA GPC-3 mRNA level, Inhibited (%) the inhibited percentage, P
values the data were calculated by Dunnett’s t method
a The inhibited (%)01−2−ΔΔCt from ΔCt0CtGPC-3−CtGAPDH and
ΔΔCt0ΔCtSample−ΔCtControl
b Compared with the control group
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Suppression of cell proliferation by shRNA1
After HepG2 cells were transfected with shRNA1, the ef-
fective and significant inhibition of cell proliferation is
shown in Fig. 3. Compared with the neg-shRNA group,
the viability after the cells transfected with shRNA1 was
notably inhibited in a time-dependent manner. The higher
death rates of the transfected cells were found significantly
in the shRNA1 group compared with the neg-shRNA group
at 24 h (33.2 vs. 2.86 %, P<0.001), 48 h (57.0 vs. 6.5 %, P<
0.001), and 72 h (71.1 vs. 10.5 %, P<0.001, Fig. 3a),
whereas the neg-shRNA group showed a similar frequency
of death as the control group. DNA synthesis and nuclear
staining in the transfected cells stained with 5-ethynyl-2′-
deoxyuridine (EdU) or Hoechst 33342 were visualized un-
der a fluorescence microscope (Fig. 3b), with apoptotic cells
showing shrunken nuclei with a bright fluorescence appear-
ance, indicating that high GPC-3 expression increases the
growth and survival of HepG2 cells in vitro.
Synergistic effect of shRNA1 plus sorafenib
After HepG2 cells were transfected with shRNA1 for 48 h,
different doses of sorafenib (from 0 to 100 μM/L) were
simultaneously added into the cells and were cocultured for
24 h; the synergistic effects of shRNA1 plus sorafenib on cell
growth evaluated by an MTT assay are shown in Table 3.
GPC-3 expression in HepG2 cell was downregulated notably
by shRNA in a dose-dependent manner. The combination of
shRNA1 plus sorafenib has showed higher inhibition effects
(P<0.001) on cell proliferation, which demonstrated that the
synergistic effect on cell proliferation can be inhibited after the
cells were transfected with shRNA1 plus sorafenib.
Alteration of HepG2 cell cycles after shRNA1 transfection
After HepG2 cells were transfected with shRNA1, the alter-
ation of cell cycles by FACS analysis of PI-stained cells is
shown in Fig. 4. The portion of G1 phase cells was increased
by approximately 35.98 % (t0−6.382, P00.024), and the
portion of G2/M phase cells was decreased by a comparable
degree. The stable silencing of GPC-3 dramatically sup-
pressed the HepG2 cells’ cycle progression and arrested in
G1 phase, which indicated that silencing of GPC-3 gene
could inhibit effectively the proliferation and growth of
HepG2 cells by G1 phase arrest.
Fig. 2 Suppression of GPC-3 expression after HepG2 cells were
transfected with different shRNAs. a After HepG2 cells were trans-
fected with different shRNAs at 24 h, the alterations of GPC-3 expres-
sion at protein level were analyzed by Western blotting as described in
“Materials and methods.” Lane 1, the control (the untreated cells,
vehicle), 2 the neg-shRNA, 3 the shRNA1, 4 the shRNA2, 5 the
shRNA3, and 6 the shRNA4. b The ratio of GPC-3 protein expression.
Data were expressed as mean ± SD from three independent experi-
ments. *P<0.05, **P<0.01, and ***P<0.001 vs. the neg-shRNA
group
Fig. 3 The effect of silencing GPC-3 on HepG2 cell growth and
survival. a The downregulation of GPC-3 expression inhibited the
HepG2 cell viability with a time-dependent manner. Data represented
the mean ± SD from three independent experiments. b After the
HepG2 cells (×200) were transfected with shRNA and stained with
EdU and Hoechst 33342. At 48 h, the cells were plated in 96-well
plates (2.0×103cells/well) in triplicate for another 24 h, then exposed
to EdU for 2 h, and visualized under a fluorescence microscope. EGFP
(green) labeled by EdU was shown with double white arrows, and the
single white arrow showed that the cells had been induced to apoptosis
after silencing GPC-3 by shRNA1. EdU (red), DNA synthesis;
Hoechst 33342 (blue), nuclear staining; apoptotic cells (white arrows)
showed shrunken nuclei with a bright fluorescent appearance
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Increase in HepG2 cell apoptosis after shRNA1 transfection
The potential effects of shRNA-mediated GPC-3 silencing on
cell apoptosis with an Annexin V-PE/7-AAD assay by flow
cytometry are shown in Fig. 5. Compared with the control
(3.34 %, Fig. 5, A1) or negative-shRNA (6.92 %, Fig. 5, A2)
group, the number of apoptotic HepG2 cells was significantly
increased in the shRNA1 group (66.75 %, Fig. 5, A3). The
apoptosis rate of HepG2 cells was increased significantly
(Fig. 5b, t0−11.456, P00.008). In order to further evaluate
the effects of shRNA1 transfection on cell apoptosis, the DNA
degradation from HepG2 cells was observed obviously on
DNA-ladder electrophoresis (Fig. 5c) in the shRNA1 group,
whereas this was not detected in the negative or control group,
suggesting that the inhibition of GPC-3 can remarkably in-
duced apoptosis of HepG2 cells.
Discussion
HCC is a common malignant disease with poor prognosis
[19, 20]. Its underlying molecular mechanism provides a
potential in developing new therapeutic target, which is very
urgent [21, 22]. GPC-3 is a 66-kDa protein, which belongs
to the family of heparan sulfate proteoglycans, bound to the
cell surface by a glycosylphosphatidylinositol anchor. It is
significantly overexpressed in HCC, embryo tissues, fetal
liver, and trophoblastic cells and has little or no expression
in adult tissues except for normal lung, ovarian, mammary
epithelial, and mesothelial tissues [23, 24]. Previous studies
have shown that GPC-3 as an oncofetal protein was abnor-
mally expressed during HCC development in human or
animal models [17]. In this study, specific and efficient
shRNA plasmids were constructed to explore the effect of
GPC-3 downregulation on the growth, as well as apoptosis-
related mechanisms, of hepatoma cells, and it was found out
that they inhibited successfully and effectively the GPC-3
expression of human HepG2 cells.
GPC-3 is essential for proper embryogenesis and represents a
promising target structure [25, 26]. Variant approaches for the
functional characterization of GPC-3 in different cell types have
been developed [27, 28]. However, these strategies cannot have
specificity, efficiency, stability, and nontoxicity at the same time.
A developing RNAi strategy is a powerful technique to inhibit
specific gene expression, exhibit the potential to study gene
function, or explore new tumor therapeutic agents [29, 30]. In
the present study, four kinds of GPC-3-targeting shRNA expres-
sion vectors were applied (pGPU6/GFP/NeoGPC-3shRNA1, 2,
3, and 4) to target GPC-3 gene sites. The most significant
inhibition of GPC-3 expression at RNA level was that of the
shRNA1 groups, indicating that special shRNA application
could be an effective GPC-3 gene-silencing method. Further
studies revealed that the level of GPC-3 gene and its expression
was significantly decreased in the shRNA1-transfected cells
compared with untreated and control cell groups, suggesting
that shRNA1 not only intervened the expression of GPC-3 gene
but also inhibited the action of transcription.
shRNA1 downregulated GPC-3 expression to suppress
tumor cell proliferation and had a synergistic effect with
chemotherapy drug. After HepG2 cells were transfected
with shRNA1, the effects of downregulated GPC-3 expres-
sion on cell proliferation were investigated in the present
Table 3 Synergistic effect of HepG2 cell proliferation after shRNA1 transfection with different doses of sorafenib (n05)
Group Control neg-shRNA shRNA1 + sorafenib t value P value
0 μM 1.23±0.05 1.22±0.03 0.96±0.24a 2.147 0.040
2.5 μM 1.20±0.05 1.17±0.02 0.73±0.03a 14.972 <0.001
5 μM 1.15±0.04 1.16±0.02 0.68±0.04a 15.805 <0.001
10 μM 1.08±0.03 1.05±0.08 0.54±0.03a 23.314 <0.001
20 μM 1.02±0.03 1.00±0.03 0.51±0.03a 18.713 <0.001
50 μM 0.96±0.05 0.94±0.07 0.36±0.03a 19.221 <0.001
100 μM 0.86±0.01 0.86±0.06 0.17±0.02a 50.352 <0.001
neg-shRNA the negative shRNA, shRNA1 the GPC-3-shRNA1
*Compared with the control group
Fig. 4 Alteration of cell cycles after HepG2 cells were transfected
with shRNA1. The cell cycle progression was inhibited through G1
arrest and increased up to 35.98 % compared with the control group
(t0−6.382, P00.024). Apoptotic cells were examined after cells
stained with Annexin V-PE/7-AAD were analyzed by flow cytometry
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study. GPC-3-shRNA1 remarkably downregulated the
GPC-3 expression of HepG2 cells at the mRNA or protein
level, with 71.1 % of cell proliferation suppression at 72 h;
the cell cycle arrested at G1 phase and notably induced the
HepG2 cell apoptosis. To further evaluate the effect of
shRNA and chemotherapy drug on HepG2 cells, different
doses of sorafenib were added into the transfected cells, and
the result demonstrated that shRNA and sorafenib have a
synergistic effect on the inhibition of HepG2 cell prolifera-
tion, suggesting that knockdown GPC-3 gene could effec-
tively and significantly suppress the proliferation and induce
apoptosis, and confirming that GPC-3 is a potential effective
target for HCC therapy [31, 32].
The molecular biology of carcinogenesis and tumor pro-
gression of HCC has been increasingly understood with
intense research in recent years [33, 34]. The heterogeneity
of HCC molecular pathology poses a formidable obstacle to
the development of noncytotoxic therapies. Several protu-
morigenic signaling pathways can be aberrantly activated in
HCC, including those triggered by Wnts. GPC-3, a
membrane-bound heparan sulfate proteoglycan that is over-
expressed in most HCCs, promotes the tumor growth by
stimulating Wnt signaling, because GPC-3 binds with high
affinity to Wnts and its growth-promoting activity requires
attachment to the cell membrane [13, 14]. The role of
several growth factors and angiogenic factors has been
confirmed. Effective agents targeting these molecular ab-
normalities have been developed and widely tested in pre-
clinical studies of HCC cell lines or xenograft models [25].
In summary, the management of advanced HCC is enter-
ing the era of molecular targeting therapy [35, 36], which is
of particular significance for HCC in view of the lack of
existing effectively systemic therapy for HCC. The tran-
scription and activation of intervened GPC-3 gene by spe-
cific shRNA expression of vector mediated RNAi were
successfully used to suppress the GPC-3 expression in hu-
man HepG2 cells with the viable alteration, proliferation
inhibition, and apoptosis occurrence of hepatoma cells.
The present data made it clear that GPC-3 plays an impor-
tant role in HCC, and it should be a promising and potential
molecular therapeutic target for HCC to improve prognosis.
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Fig. 5 Apoptosis increased after HepG2 cells were transfected with
shRNA1. a The number of apoptotic cells of the knockdown group was
significantly higher than the negative or control group. b The number
of cells with nuclear morphological features of apoptosis was counted
after staining with Hoechst 33342. Data are expressed as percentage of
apoptotic cells based on counting 100 cells in randomly selected fields.
Data are from three separate experiments (mean ± SD). c DNA was
extracted and DNA-ladder electrophoresis assay was used to detect
apoptosis. 1, DNA marker; 2, the control group; 3, the negative-
shRNA; and 4, the shRNA1 group. When the cells were apoptotic,
the DNA was degraded and the DNA ladder would be detected on
agarose gel electrophoresis. **P<0.01
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